Biogen (BIIB) to Release Earnings on Thursday

Biogen (NASDAQ:BIIB - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Thursday, July 31st. Analysts expect Biogen to post earnings of $4.11 per share and revenue of $2.32 billion for the quarter. Biogen has set its FY 2025 guidance at 14.500-15.500 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share for the quarter, missing analysts' consensus estimates of $3.26 by ($0.24). The company had revenue of $2.43 billion for the quarter, compared to analysts' expectations of $2.25 billion. Biogen had a net margin of 15.07% and a return on equity of 14.03%. Biogen's quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the firm earned $3.67 earnings per share. On average, analysts expect Biogen to post $16 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Biogen Stock Performance

Shares of BIIB traded down $1.07 during trading hours on Friday, reaching $131.52. 976,978 shares of the company traded hands, compared to its average volume of 1,173,055. The stock has a market capitalization of $19.27 billion, a P/E ratio of 12.98, a P/E/G ratio of 1.91 and a beta of 0.14. The company has a quick ratio of 1.01, a current ratio of 1.44 and a debt-to-equity ratio of 0.27. Biogen has a 12-month low of $110.04 and a 12-month high of $219.44. The business has a fifty day moving average price of $129.74 and a 200-day moving average price of $132.51.

Wall Street Analyst Weigh In

BIIB has been the topic of a number of research analyst reports. HSBC lowered shares of Biogen from a "buy" rating to a "hold" rating and set a $118.00 price objective on the stock. in a report on Monday, April 28th. Canaccord Genuity Group decreased their price objective on shares of Biogen from $265.00 to $220.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Needham & Company LLC reiterated a "hold" rating on shares of Biogen in a research report on Thursday, June 12th. Royal Bank Of Canada set a $213.00 price objective on shares of Biogen and gave the stock an "outperform" rating in a research report on Wednesday, June 25th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Biogen from $185.00 to $175.00 and set a "neutral" rating for the company in a research report on Monday, May 5th. Twenty-one analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $186.37.

Insider Activity at Biogen

In other news, insider Rachid Izzar sold 2,223 shares of the company's stock in a transaction that occurred on Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total value of $300,105.00. Following the transaction, the insider directly owned 6,330 shares in the company, valued at approximately $854,550. This represents a 25.99% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.18% of the company's stock.

Institutional Investors Weigh In On Biogen

An institutional investor recently raised its position in Biogen stock. Empowered Funds LLC boosted its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 64.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,054 shares of the biotechnology company's stock after buying an additional 2,777 shares during the quarter. Empowered Funds LLC's holdings in Biogen were worth $965,000 as of its most recent SEC filing. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.